Holen Sie sich die Stockscreener-App
5.9785
4.74%
0.2785
Schlusskurs vom Vortag:
$5.70
Offen:
$5.75
24-Stunden-Volumen:
1.96M
Relative Volume:
0.40
Marktkapitalisierung:
$1.56B
Einnahmen:
$6.22B
Nettoeinkommen (Verlust:
$187.00M
KGV:
8.3429
EPS:
0.7166
Netto-Cashflow:
$508.00M
1W Leistung:
-2.29%
1M Leistung:
-18.11%
6M Leistung:
-44.10%
1J Leistung:
-59.91%
1-Tages-Spanne:
$5.735
$5.99
1-Wochen-Bereich:
$5.69
$6.285
52-Wochen-Spanne:
$5.69
$14.90
Organon Co Stock (OGN) Company Profile
Firmenname
Organon Co
Sektor
Telefon
551-430-6000
Adresse
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
5.985 | 1.48B | 6.22B | 187.00M | 508.00M | 0.7166 |
LLY
Lilly Eli Co
|
920.47 | 792.08B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
244.25 | 584.06B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
217.68 | 376.96B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
196.16 | 300.68B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.08 | 291.99B | 64.93B | 18.26B | 12.36B | 7.2751 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Underweight |
| 2025-10-27 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-09-06 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-11-03 | Herabstufung | Goldman | Buy → Neutral |
| 2023-09-21 | Eingeleitet | Barclays | Overweight |
| 2023-03-16 | Eingeleitet | Raymond James | Outperform |
| 2022-10-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Eingeleitet | Piper Sandler | Neutral |
| 2021-09-01 | Eingeleitet | BofA Securities | Buy |
| 2021-07-22 | Eingeleitet | Citigroup | Buy |
| 2021-06-15 | Eingeleitet | JP Morgan | Neutral |
| 2021-06-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-10 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Organon Co Aktie (OGN) Neueste Nachrichten
Organon & Co stock hits 52-week low at $5.76 By Investing.com - Investing.com Australia
Organon & Co. (OGN) is a trending stock: Facts to know before betting on it - MSN
Organon & Co. (NYSE:OGN) Hits New 12-Month LowHere's What Happened - MarketBeat
Organon & Co. (OGN) Is Gaining Attention: Key Information to Consider Before Investing - bitget.com
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Evaluating Organon (OGN) After A Steep Share Price And One Year Return Decline - simplywall.st
Organon & Co Stock: Steady Healthcare Player with Growth Potential Amid Market Pressures - AD HOC NEWS
Organon presents VTAMA cream data for atopic dermatitis at AAD By Investing.com - Investing.com Australia
Organon (OGN) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Organon to present results from Phase 3 Adoring 1, Adoring 2 on Vtama cream - TipRanks
Vanguard disaggregates holdings; reports 0 shares of Organon (OGN) - Stock Titan
Organon & Co. (NYSE:OGN) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
Organon presents VTAMA cream data for atopic dermatitis at AAD - Investing.com
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age - Business Wire
FRA:7XP PB Ratio: 2.12 — 60% Below Median - GuruFocus
Is It Time To Reassess Organon (OGN) After Its Sharp Share Price Slide - simplywall.st
Organon & Co. Stock Plummets to New 52-Week Low of $5.76 - Markets Mojo
Organon & Co stock faces renewed scrutiny amid women's health sector shifts and pipeline updates - AD HOC NEWS
Organon sees opportunities in China's push for high-quality population development - China Daily
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - MSN
Organon: A High Cash Yield Hidden Behind Patent Fatigue - gurufocus.com
Organon & Co. (NYSE:OGN) Hits New 52-Week LowHere's Why - MarketBeat
Organon & Co. Hits New 52-Week Low at USD 6.16 Amidst Declining Performance - Markets Mojo
Assessing Organon (OGN) Valuation After Prolonged Share Price Weakness And A 33% Undervaluation Estimate - simplywall.st
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? - The Motley Fool
Does a $25 Million Investment in a Stock That Has Fallen 61% Indicate a Possible Recovery at $6? - Bitget
Sio Capital's New Organon Investment: A Value Play in Women's HealthNews and Statistics - IndexBox
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? - The Motley Fool
Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility - MSN
Behavioral Patterns of OGN and Institutional Flows - Stock Traders Daily
Organon & Co stock hits 52-week low at 6.17 USD By Investing.com - Investing.com South Africa
Organon & Co stock hits 52-week low at 6.17 USD - Investing.com Australia
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Organon rises after update on independent review - MSN
Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility (IJR:NYSEARCA) - Seeking Alpha
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Investors heavily search Organon & Co. (OGN): Here is what you need to know - MSN
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance
Aug Wrap: Can Organon Co expand into new marketsWeekly Trade Recap & Reliable Volume Spike Alerts - baoquankhu1.vn
Organon & Co. Experiences Evaluation Revision Amidst Market Challenges and Performance Divergence - Markets Mojo
Gotham Asset Management LLC Buys 1,007,691 Shares of Organon & Co. $OGN - MarketBeat
Organon (OGN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Is Organon (OGN) Mispriced After A 58% One Year Share Price Slump? - simplywall.st
Organon & Co. (OGN) Dividend Yield 2026, Date & History $OGN - MarketBeat
OGN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Organon Q4 2025 slides: Revenue declines accelerate, stock tumbles on earnings miss - Investing.com Nigeria
Organon trades in red for seven straight sessions - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Organon & Co. (OGN) And Encourages Shareholders to Reach Out - ACCESS Newswire
(OGN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Organon Q3 Net Margin Squeeze Challenges Bullish Earnings Growth Narratives - Sahm
Organon Stock Tumbles To Record Low On Downgrades And Dividend Cut: Retail Optimism Persists - MSN
Finanzdaten der Organon Co-Aktie (OGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Organon Co-Aktie (OGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Drinane Juliana Papa | Interim Head of Mfg & Supply |
Nov 07 '25 |
Option Exercise |
0.00 |
3,626 |
0 |
18,417 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO |
Nov 07 '25 |
Option Exercise |
0.00 |
6,446 |
0 |
31,223 |
| Holzbaur Lynette | SVP and Corporate Controller |
Nov 07 '25 |
Option Exercise |
0.00 |
2,417 |
0 |
15,365 |
| Holzbaur Lynette | SVP and Corporate Controller |
Nov 05 '25 |
Option Exercise |
0.00 |
3,037 |
0 |
13,814 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO |
Aug 11 '25 |
Option Exercise |
0.00 |
11,519 |
0 |
28,899 |
| COX CARRIE SMITH | Director |
May 14 '25 |
Buy |
8.07 |
12,469 |
100,591 |
12,469 |
| Falcione Aaron | Chief Human Resources Officer |
May 07 '25 |
Buy |
8.77 |
5,500 |
48,235 |
62,974 |
| Weaver Kirke | Gen. Counsel & Corp. Secy. |
May 06 '25 |
Buy |
9.21 |
8,045 |
74,054 |
52,489 |
| Karp Daniel | Executive VP, Corp. Dev. |
May 06 '25 |
Buy |
8.24 |
3,500 |
28,828 |
46,669 |
| WALSH MATTHEW M | Chief Financial Officer |
May 05 '25 |
Buy |
8.82 |
11,400 |
100,548 |
144,484 |
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):